This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Diener-West, M. Articles by Thoma, J. Search for Related Content PubMed PubMed Citation Articles by Diener-West, M. Articles by Thoma, J. Social Bookmarking                            What's this?

Screening for Metastasis From Choroidal Melanoma: The Collaborative Ocular Melanoma Study Group Report 23

From the The Wilmer Ophthalmological Institute, Johns Hopkins University, Baltimore, MD; Midwest Eye Institute, Indianapolis, IN; Jules Stein Eye Institute, University of California Los Angeles, Los Angeles, CA; Mayo Clinic, Jacksonville, FL; Retina-Vitreous Consultants; University of Pittsburgh, Pittsburgh, PA; University of Michigan, Ann Arbor; Associated Retinal Consultants; Beaumont Cancer Center, Royal Oak, MI; University of Washington, Seattle, WA; Mayo Clinic, Rochester, MN; Northwestern University, Chicago, IL; and The University of Virginia, Charlottesville, VA

Address reprint requests to Marie Diener-West, PhD, COMS Coordinating Center, Wilmer Clinical Trials and Biometry, 550 N Broadway, Floor 9, Baltimore, MD 21205; e-mail: mdiener{at}jhsph.edu

PURPOSE: To describe the predictive value of liver function tests (LFTs), chest x-ray, and diagnostic imaging for detecting melanoma metastasis during routine follow-up after treatment for choroidal melanoma.

MATERIALS AND METHODS: Prospective longitudinal follow-up of patients enrolled onto two randomized trials was conducted by the Collaborative Ocular Melanoma Study (COMS) Group. Baseline and annual or semiannual systemic and laboratory evaluations were performed according to a standard protocol for 2,320 patients enrolled on the COMS.

RESULTS: COMS patients were screened annually for metastasis and new cancers using LFTs (alkaline phosphatase, AST, ALT, or bilirubin). Elevated findings (1.5 to 2 times upper limit of normal) on LFT prompted a diagnostic or imaging test to confirm or rule out cancer recurrence. Of 714 patients with clinical reports of metastasis, 675 patients died. Of these 675 patients, all but four had either histopathologically confirmed or clinically suspected metastatic melanoma present at the time of death. Among all patients, the 5-year cumulative diagnosis rate of metastatic melanoma was 24% (95% CI, 22% to 27%). Based on all patients with reported metastasis, the sensitivity, specificity, positive predictive value and negative predictive value associated with at least one abnormal LFT before first diagnosis of metastasis at any site was 14.7%, 92.3%, 45.7% and 71.0%, respectively.

CONCLUSION: Use of LFTs results followed by diagnostic tests has high specificity and predictive values but low sensitivity. Better tests are needed to identify earlier metastatic disease associated with choroidal melanoma.

Supported by the National Eye Institute and the National Cancer Institute through cooperative agreements EY06253, EY06257, EY06258, EY06259, EY06020, EY06264, EY06265, EY06266, EY06268, EY06269, EY06270, EY06274, EY06275, EY06276, EY06279, EY06280, EY06282, EY06283, EY06284, EY06287, EY06288, EY06289, EY06291, EY06839, EY06843, EY06844, EY06848, EY06858, EY06899 with the National Institutes of Health, Bethesda, MD.

A complete list of the COMS Group members as of September 30, 2000, is in Arch Ophthalmol 119:961–965, 2001.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. L. Shields, M. Furuta, A. Thangappan, S. Nagori, A. Mashayekhi, D. R. Lally, C. C. Kelly, D. S. Rudich, A. V. Nagori, O. A. Wakade, et al. Metastasis of Uveal Melanoma Millimeter-by-Millimeter in 8033 Consecutive Eyes Arch Ophthalmol, August 1, 2009; 127(8): 989 - 998. [Abstract] [Full Text] [PDF]

				V. Barak, S. Frenkel, K. Valyi-Nagy, L. Leach, M. A. Apushkin, A. Y. Lin, I. Kalickman, N. A. Baumann, J. Pe'er, A. J. Maniotis, et al. Using the Direct-Injection Model of Early Uveal Melanoma Hepatic Metastasis to Identify TPS as a Potentially Useful Serum Biomarker Invest. Ophthalmol. Vis. Sci., October 1, 2007; 48(10): 4399 - 4402. [Abstract] [Full Text] [PDF]

				E. S. Gragoudas Proton Beam Irradiation of Uveal Melanomas: The First 30 Years The Weisenfeld Lecture Invest. Ophthalmol. Vis. Sci., November 1, 2006; 47(11): 4666 - 4673. [Full Text] [PDF]

				P. L. Blanco, J. C. A. Marshall, E. Antecka, S. A. Callejo, J. P. Souza Filho, V. Saraiva, and M. N. Burnier Jr Characterization of Ocular and Metastatic Uveal Melanoma in an Animal Model Invest. Ophthalmol. Vis. Sci., December 1, 2005; 46(12): 4376 - 4382. [Abstract] [Full Text] [PDF]

				Collaborative Ocular Melanoma Study Group* Development of Metastatic Disease After Enrollment in the COMS Trials for Treatment of Choroidal Melanoma: Collaborative Ocular Melanoma Study Group Report No. 26 Arch Ophthalmol, December 1, 2005; 123(12): 1639 - 1643. [Abstract] [Full Text] [PDF]

				P. Rietschel, K. S. Panageas, C. Hanlon, A. Patel, D. H. Abramson, and P. B. Chapman Variates of Survival in Metastatic Uveal Melanoma J. Clin. Oncol., November 1, 2005; 23(31): 8076 - 8080. [Abstract] [Full Text] [PDF]

				P T Finger, M Kurli, S Reddy, L B Tena, and A C Pavlick Whole body PET/CT for initial staging of choroidal melanoma Br J Ophthalmol, October 1, 2005; 89(10): 1270 - 1274. [Abstract] [Full Text] [PDF]